ABT vs PLSE
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. PLSE: Pulse Biosciences is developing a novel nanosecond pulsed-field ablation platform aimed at transforming the treatment of atrial fibrillation and soft tissue conditions.
Side-by-side fundamentals
| Metric | ABT | PLSE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $98.49 | $49.98 | |
| Market cap | $171.6B | $3.6B | |
| P/E as of 2026-10-08 | 31.70 | n/a | |
| Net margin FY2025, SEC XBRL | +14.7% | -20794.6% | ABT higher |
| Operating margin FY2025, SEC XBRL | +18.2% | -21982.6% | ABT higher |
| ROE FY2025, SEC XBRL | +12.4% | -90.2% | ABT higher |
| ROA FY2025, SEC XBRL | +7.5% | -77.0% | ABT higher |
| Debt / equity as of 2026-09-03 | 0.64 | 0.00 | PLSE lower |
| Revenue growth (YoY) as of 2026-09-03 | +8.1% | -20.6% | ABT higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | -20.6% | ABT higher |
| Dividend yield as of 2026-09-03 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | ABT higher |
| Beta as of 2026-09-03 | 0.18 | 1.01 | |
| 1-year return as of 2026-10-08 close | -26.6% | +150.7% | PLSE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.